Prostate And Other Male Cancers

Efficacy, Safety of PSA Testing for Prostate Cancer Screening Investigated

September 06, 2018

Odds of choosing screening up for men with family history, African descent, low socioeconomic status

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

August 13, 2018

Prostate cancer patients with a rapidly risking prostate-specific antigen (PSA) despite chemical or physical castration had lower rates of metastasis when treated with enzalutamide compared to those in a placebo group.

FDA Approves Expanded Prostate Cancer Indication for Xtandi

By July 16, 2018

The approval was based on data from the Phase 3 PROSPER trial which enrolled 1401 patients with non-metastatic CRPC.

Prostate Cancer Treatment Side Effects Linked to Distress

June 08, 2018

This relationship was bidirectional, with men who reported worse distress also subsequently reporting worse urinary, bowel, and sexual functions.

Yonsa Approved for Metastatic Castration-Resistant Prostate Cancer

By May 23, 2018

The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.

AUA Updates Castration-Resistant Prostate Cancer Clinical Guideline

By May 18, 2018

"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.

Wine Consumption and Prostate Cancer Risk: Is There a Link?

May 14, 2018

In multivariable analysis, moderate white wine consumption increased the risk of prostate cancer (pooled risk ratio, 1.26; 95% confidence interval, 1.10 to 1.43; P=.001).

USPSTF: Final Recommendation Statement on Prostate Cancer Screening

By May 09, 2018

The Task Force recommends that for men 55 to 69 years of age, the decision to undergo prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.

Cancer Incidences and Burden Expected to Shift in HIV-Positive

May 08, 2018

The estimated total cancer burden in PLWH will decrease from 8,150 cases in 2010 to 6,690 cases in 2030, with prostate and lung cancer projected to be the most common cancer types.

Spermatogenesis Still Occurs in Men With Testicular Cancer

April 27, 2018

"These findings can help predict and guide successful surgical sperm retrieval in testes with testicular germ cell tumors," the authors write.

TFs Operate Across Gene Loci Within Disease Phenotypes

April 16, 2018

"Our results nominate mechanisms that operate across risk loci within disease phenotypes, suggesting new models for disease origins," the authors write.

Group Exercise, Nutrition Aids Prostate Cancer Patients on ADT

April 10, 2018

At the 3-month follow-up, EX+D resulted in significantly greater improvements in mobility performance (P<0.02), muscular strength (P<0.01), body fat percentage (P<0.05), and fat mass (P<0.03), when controlling for baseline and androgen-deprivation therapy

Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer

March 29, 2018

The researchers observed a greater effect on PSA in the LOW arm versus the STD arm (mean log-change, −1.59 versus −1.19); according to predefined criteria, the noninferiority of LOW was established.

Can Radiation Dose-Escalation Up Survival in Prostate CA?

March 16, 2018

The 8-year rates of OS were 76 and 75% with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95% confidence interval, 0.83 to 1.20; P=0.98). The 8-year cumulative rates of distant metastases were 4 and 6% for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95% confidence interval, 0.42 to 1.01; P=0.05).

Erleada Approved for Non-Metastatic, Castration-Resistant Prostate Cancer

By February 15, 2018

Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.

Positive Results Released for Novel Prostate Cancer Tx

February 09, 2018

The researchers found that the median metastasis-free survival was 40.5 months in the apalutamide group and 16.2 months in the placebo group in the planned primary analysis performed after 378 events had occurred. Also significantly longer time to symptomatic progression was seen with apalutamide versus placebo.

Zytiga Approved for Metastatic High-Risk Castration-Sensitive Prostate Cancer

By February 08, 2018

The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.

Obesity and Prostate CA Recurrence: What's the Link?

January 26, 2018

The researchers found that there were more obese patients in the high- versus low-/intermediate-risk group (41.2 versus 32.0%; P=0.006).

Mediterranean Diet Linked to Reduced Risk of Aggressive Prostate Cancer

January 18, 2018

The researchers found that high adherence to a Mediterranean dietary pattern, rich in fruits and vegetables, fish, legumes, and olive oil, correlated with a lower risk of prostate cancer with a Gleason score greater than 6.

Personalized Genetic Test May Estimate Age of Prostate CA Diagnosis

January 12, 2018

"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.

Enzalutamide Seizure Risk Factor Assessed in mCRPC

December 08, 2017

Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.

NDA Submitted for Novel Non-Metastatic CRPC Treatment

By October 11, 2017

Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Genetics Should Play a Bigger Role in Clinical Decision-Making

June 21, 2017

As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.

Efficacy of Abiraterone Examined in Newly Diagnosed Prostate CA

June 06, 2017

Researchers of 2 newly published studies found that abiraterone (Zytiga) lowers risk of death by nearly 40% when added to standard androgen deprivation therapy.

Existing Treatment Effective in Bile Duct CA Following Surgery

May 22, 2017

In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

New Zytiga Tablet Strength Available

By May 17, 2017

Zytiga was shown to lower serum testosterone and other androgens in patients enrolled in a Phase 3 placebo-controlled trial.

AUA 'Choosing Wisely' List IDs Unnecessary Tests, Treatments

By May 15, 2017

The 2017 AUA list contains evidence-based recommendations to guide conversations between physicians and patients about what care is appropriate.

Italian-Style Coffee Consumption May Reduce Prostate Cancer Risk

By April 26, 2017

Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.